CHAPTER 1. Industry Overview of Benign Prostatic Hyperplasia Therapeutics Market
1.1. Definition and Scope
1.1.1. Definition of Benign Prostatic Hyperplasia Therapeutics
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Benign Prostatic Hyperplasia Therapeutics Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Benign Prostatic Hyperplasia Therapeutics Market By Therapeutics Class
1.2.3. Benign Prostatic Hyperplasia Therapeutics Market By Therapy
1.2.4. Benign Prostatic Hyperplasia Therapeutics Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Benign Prostatic Hyperplasia Therapeutics Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Benign Prostatic Hyperplasia Therapeutics Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2022
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Benign Prostatic Hyperplasia Therapeutics Market By Therapeutics Class
4.1. Introduction
4.2. Benign Prostatic Hyperplasia Therapeutics Market Revenue By Therapeutics Class
4.2.1. Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast, By Therapeutics Class, 2020-2032
4.2.2. Alpha blockers
4.2.2.1. Alpha blockers Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
4.2.3. Phosphodiesterase-5 Inhibitors
4.2.3.1. Phosphodiesterase-5 Inhibitors Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
4.2.4. 5-Alpha Reductase Inhibitors
4.2.4.1. 5-Alpha Reductase Inhibitors Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
4.2.5. Others
4.2.5.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 5. Benign Prostatic Hyperplasia Therapeutics Market By Therapy
5.1. Introduction
5.2. Benign Prostatic Hyperplasia Therapeutics Market Revenue By Therapy
5.2.1. Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast, By Therapy, 2020-2032
5.2.2. Mono Drug Therapy
5.2.2.1. Mono Drug Therapy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. Combination Drug Therapy
5.2.3.1. Combination Drug Therapy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. North America Benign Prostatic Hyperplasia Therapeutics Market By Country
6.1. North America Benign Prostatic Hyperplasia Therapeutics Market Overview
6.2. U.S.
6.2.1. U.S. Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
6.2.2. U.S. Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
6.3. Canada
6.3.1. Canada Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
6.3.2. Canada Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
6.4. North America PEST Analysis
CHAPTER 7. Europe Benign Prostatic Hyperplasia Therapeutics Market By Country
7.1. Europe Benign Prostatic Hyperplasia Therapeutics Market Overview
7.2. U.K.
7.2.1. U.K. Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
7.2.2. U.K. Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
7.3. Germany
7.3.1. Germany Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
7.3.2. Germany Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
7.4. France
7.4.1. France Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
7.4.2. France Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
7.5. Spain
7.5.1. Spain Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
7.5.2. Spain Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
7.6. Rest of Europe
7.6.1. Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
7.6.2. Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
7.7. Europe PEST Analysis
CHAPTER 8. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market By Country
8.1. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Overview
8.2. China
8.2.1. China Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
8.2.2. China Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
8.3. Japan
8.3.1. Japan Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
8.3.2. Japan Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
8.4. India
8.4.1. India Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
8.4.2. India Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
8.5. Australia
8.5.1. Australia Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
8.5.2. Australia Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
8.6. South Korea
8.6.1. South Korea Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
8.6.2. South Korea Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
8.7. Rest of Asia-Pacific
8.7.1. Rest of Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
8.7.2. Rest of Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
8.8. Asia Pacific PEST Analysis
CHAPTER 9. Latin America Benign Prostatic Hyperplasia Therapeutics Market By Country
9.1. Latin America Benign Prostatic Hyperplasia Therapeutics Market Overview
9.2. Brazil
9.2.1. Brazil Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
9.2.2. Brazil Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
9.3. Mexico
9.3.1. Mexico Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
9.3.2. Mexico Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
9.4. Rest of Latin America
9.4.1. Rest of Latin America Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
9.4.2. Rest of Latin America Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
9.5. Latin America PEST Analysis
CHAPTER 10. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market By Country
10.1. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Overview
10.2. GCC
10.2.1. GCC Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
10.2.2. GCC Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
10.3. South Africa
10.3.1. South Africa Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
10.3.2. South Africa Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
10.4. Rest of Middle East & Africa
10.4.1. Rest of Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapeutics Class, 2020-2032
10.4.2. Rest of Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Revenue (USD Billion) and Forecast By Therapy, 2020-2032
10.5. Middle East & Africa PEST Analysis
CHAPTER 11. Player Analysis Of Benign Prostatic Hyperplasia Therapeutics Market
11.1. Benign Prostatic Hyperplasia Therapeutics Market Company Share Analysis
11.2. Competition Matrix
11.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
11.2.2. New Product Launches and Product Enhancements
11.2.3. Mergers And Acquisition In Global Benign Prostatic Hyperplasia Therapeutics Market
11.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 12. Company Profile
12.1. Abbott Laboratories
12.1.1. Company Snapshot
12.1.2. Business Overview
12.1.3. Financial Overview
12.1.3.1. Revenue (USD Billion), 2022
12.1.3.2. Abbott Laboratories 2022 Benign Prostatic Hyperplasia Therapeutics Business Regional Distribution
12.1.4. Product /Service and Specification
12.1.5. Recent Developments & Business Strategy
12.2. AbbVie (Allergan Plc)
12.3. Astellas Pharma Inc.
12.4. Boehringer Ingelheim Pharma GmbH & Co. KG
12.5. Eli Lilly and Company
12.6. GlaxoSmithKline plc.
12.7. Merck & Co., Inc. (Merck Sharp & Dohme Corp)
12.8. Pfizer Inc.
12.9. Sanofi
12.10. Teva Pharmaceutical Industries Limited
The market size of benign prostatic hyperplasia therapeutics was USD 7.9 billion in 2022.
The CAGR of benign prostatic hyperplasia therapeutics is 5.1% during the analysis period of 2023 to 2032.
The key players operating in the global market are including Abbott Laboratories, AbbVie (Allergan Plc), Astellas Pharma Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc., Merck & Co., Inc. (Merck Sharp & Dohme Corp), Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Limited.
North America held the dominating position in benign prostatic hyperplasia therapeutics industry during the analysis period of 2023 to 2032.
Asia-Pacific region exhibited fastest growing CAGR for market of benign prostatic hyperplasia therapeutics during the analysis period of 2023 to 2032.
The current trends and dynamics in the benign prostatic hyperplasia therapeutics industry include increasing prevalence of BPH among aging male population, growing awareness about BPH and its impact on quality of life, and rising demand for non-surgical treatment options
The Alpha blockers held the maximum share of the benign prostatic hyperplasia therapeutics industry.?
Customer Satisfaction
Availability - we are always there when you need us
Fortune 50 Companies trust Acumen Research and Consulting
of our reports are exclusive and first in the industry
more data and analysis
reports published till date